Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19197783 | 0.88 | KCNH2 (0.47) | KCNH2CYP2C8CYP3A4NR1I2 | |
| SCHEMBL19198127 | 0.86 | KCNH2 (0.42) | KCNH2CYP2C8CYP3A4 | |
| SCHEMBL19198140 | 0.85 | KCNH2 (0.46) | KCNH2CYP2C8 | |
| SCHEMBL19193981 | 0.82 | ANO1 (0.36) | — | |
| SCHEMBL19197887 | 0.78 | KCNH2 (0.50) | KCNH2CYP2C8CYP3A4NR1I2 | |
| SCHEMBL1918982 | 0.78 | KCNH2 (0.52) | KCNH2CYP2C8 | |
| SCHEMBL2436747 | 0.76 | AR (0.45) | KCNH2CYP2C8CYP3A4 | |
| SCHEMBL2842305 | 0.75 | CYP3A4 (0.54) | KCNH2CYP2C8CYP3A4NR1I2 | |
| SCHEMBL6120116 | 0.74 | CYP2C9 (0.44) | KCNH2CYP2C8CYP3A4 | |
| SCHEMBL2368951 | 0.74 | KCNH2 (0.41) | KCNH2CYP2C8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202403-B2 | Macrocyclic benzofuran compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170217989-A1 | MACROCYCLIC BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202403-B2 | Macrocyclic benzofuran compounds for the treatment of hepatitis C | ZC3HAV1, HAVCR2, HCCS | KCNH2 2739/4885CYP2C8 50/4885CYP3A4 51/4885 |
| US-20170217989-A1 | MACROCYCLIC BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | ZC3HAV1, HAVCR2, HCCS | KCNH2 2739/4885CYP2C8 50/4885CYP3A4 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.